SOPHiA GENETICS SA reaffirmed revenue guidance for 2022. For the period the company is reaffirming previously provided guidance of constant currency revenue growth range of 30% to 35% for full-year 2022. Based on latest view of the impact of movements in the foreign exchange rates between key transactional currencies, including the euro, the Swiss franc, the British pound, and the Turkish lira, and the U.S. dollar, the company now expect full-year 2022 reported revenue to be at the low-end of previously provided range of $47.0 million to $49.5 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.99 USD | -1.48% | +5.50% | +5.94% |
May. 29 | Sector Update: Health Care Stocks Fall Late Afternoon | MT |
May. 29 | Sophia Genetics Rallies Wednesday after Partnering with Microsoft, Nvidia on Whole Genome Analytics Platform | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.94% | 326M | |
+8.91% | 85.92B | |
+5.14% | 77.93B | |
-16.20% | 52.89B | |
+26.18% | 48.28B | |
+28.93% | 45.38B | |
-34.05% | 40.83B | |
+66.72% | 38.78B | |
-0.36% | 27.48B | |
-26.47% | 21.52B |
- Stock Market
- Equities
- SOPH Stock
- News SOPHiA GENETICS SA
- Sophia Genetics Sa Reaffirms Revenue Guidance for 2022